Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.69 |
| ▸ | JAK3 | P52333 | 1/20 | 0.68 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16405547 | 1.00 | EGFR (0.83) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL29731545 | 0.92 | EGFR (0.79) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL869098 | 0.92 | EGFR (0.79) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL869099 | 0.92 | EGFR (0.79) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL21761366 | 0.92 | EGFR (0.84) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL16398696 | 0.91 | EGFR (0.79) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL16398699 | 0.91 | EGFR (0.79) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL19124184 | 0.91 | EGFR (0.73) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL19480001 | 0.89 | EGFR (0.83) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL26916650 | 0.89 | EGFR (0.68) | EGFRERBB2JAK3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053449-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-08-21 | — | — | US | disclosed |
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-9714235-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-20160168129-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | ABL1, MAP4K2, DMPK | EGFR 2069/4885ERBB2 489/4885HDAC3 1411/4885 |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | WNK1, ABL1, NEK4 | EGFR 1223/4885ERBB2 368/4885HDAC3 2775/4885 |
| US-20160168129-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | ABL1, MAP4K2, DMPK | EGFR 2069/4885ERBB2 489/4885HDAC3 1411/4885 |
| US-10053449-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | ABL1, MAP4K2, DMPK | EGFR 2069/4885ERBB2 489/4885HDAC3 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.